A medical device company developing an implant that stimulates the spinal cord to treat back pain is seeking $125 million in an initial public offering.
Menlo Park’s Nevro Corp., which would trade on the New York Stock Exchange as “NVRO,” hopes to commercially launch its Senza spinal cord stimulation device by early 2016, the company said in paperwork filed Friday with the Securities and Exchange Commission.
The eight-year-old company’s major shareholders include Johnson & Johnson Development Corp. and Danish drug, device and investment company Novo A/S, as well as venture capital firms Bay City Capital, Three Arch Partners, AMV Partners, Aberdare Ventures and New Enterprise Associates.
Help employers find you! Check out all the jobs and post your resume.
